(Science) A case report assessed the effect of continuous exposure to ofatumumab (Kesimpta) during pregnancy in a patient ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Actress Jamie-Lynn Sigler has multiple sclerosis (colloquially known as MS), and that's precisely why she's starring in the ...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

Kesimpta is such a drug, taken as an injection under the skin once a month. According to the MS Trust , it reduces the number of relapses by about two-thirds (70%). Safety, efficacy, and adherence ...

Ofatumumab (Kesimpta) is a human-made protein that attaches itself to certain B cells and weakens them so they can’t cause damage. Ofatumumab is FDA approved for: Clinically isolated syndrome ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (e ...

Novartis: “Kesimpta Medication Guide.” Multiplesclerosis.net: "Rituximab (Rituxan)." B-cell therapy for multiple sclerosis increases your risk for infections. Learn more about what you can do ...